



P10

JAN 2003

PCL 16B03 1.05291
GB03/3291 11522371

INVESTOR IN PEOPLE

**PRIORITY
DOCUMENT**SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 18 NOV 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated

28 August 2003
*P. Mahoney***Best Available Copy**

Patents Act 1977
(Rule 16)

THE PATENT OFFICE

A

26 JUL 2002

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)



26JUL02 0756300-1 069640
P01/7700 0.00-0217314.4

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

PW/URO

2. Patent application number

(The Patent Office will fill in this part)

0217314.4

26 JUL 2002

3. Full name, address and postcode of the or of each applicant (underline all surnames)

The University of York
Heslington
York YO10 5DD

Patents ADP number (if you know it)

7245376003

GB

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

BIOMIMETIC UROTHELIUM

5. Name of your agent (if you have one)

i.p.21 Limited

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

Norwich Research Park
Colney
NORWICH NR4 7UT

Patents ADP number (if you know it)

8097727001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

YES

a) any applicant named in part 3 is not an inventor, or

b) there is an inventor who is not named as an applicant, or

c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form 0
Description 14

Claim(s) 2

Abstract 1

Drawing(s) 2+2

10. If you are also filing any of the following, state how many against each item.

Priority documents 0

Translations of priority documents 0

Statement of inventorship and right to grant of a patent (Patents Form 7/77) 0

Request for preliminary examination and search (Patents Form 9/77) 0

Request for substantive examination (Patents Form 10/77) 0

Any other documents 0
(please specify)

11.

I/We request the grant of a patent on the basis of this application.

Signature

i.p. 21 Limited
by PW

Date

25/07/02

12. Name and daytime telephone number of person to contact in the United Kingdom

PETER WILSON

01603 457008

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

5

10

-1-

BIOMIMETIC UROTHELIUM

15

Field of the Invention

This invention relates to a method of *in vitro* cultivation of mammalian urothelium. The invention also relates to material produced by the method described.

20

Review of the Art known to the Applicant

The mammalian bladder and associated urinary tract is lined by urothelium, a highly specialised epithelium that provides an effective barrier between the urine and the underlying tissues of the body. With reference to Figure 1, which shows a schematic diagram of a section through typical, functional urothelium, the urothelium 1 is a stratified epithelium composed of basal 6, intermediate 5 and superficial 4 cells. With the exception of actively transported substances, the urothelium should be impermeable to all substances present in the urine or blood. Movement across the epithelium occurs via two parallel pathways: through the

25
30

cells (a transcellular pathway) and through the tight junctions 7 and lateral inter-cellular space (a paracellular pathway). Highly-specialised superficial or so-called "umbrella" cells 4 form a tissue-urine interface and provide the permeability barrier through the presence of: a) inter-cellular tight junctions and b) plaques of asymmetric unit membrane (AUM) that cover the apical (i.e. urine-facing) surface. The AUM plaques are unique to the urothelium and are composed of four major urothelium-specific proteins, collectively known as the uroplakins. These proteins have been isolated and cloned. There are two 4 transmembrane domain proteins (4TM proteins), UPIa and UPIb, and also two type 1 proteins, UPII and UPIII.

A very sensitive method and well-established measure of the ion permeability of epithelium is the transepithelial electrical resistance (TER). In general, leaky epithelia typically have a resistance of less than $500\Omega\text{ cm}^2$, whereas tight epithelia have resistances of greater than $500\Omega\text{ cm}^2$. As a result of its key requirement to protect underlying tissue from urine, urothelium has a characteristically high TER.

Aside from its very low passive permeability to small molecules such as urea, ammonia, water, and protons, and also to large molecules such as dextrans, urothelium also possesses an active transepithelial ion transport system. Of particular importance is the active sodium transport system. With reference to Figure 1, on the apical (urine facing) surface 2 of the urothelium 1 are located amiloride-sensitive sodium channels 8. On the baso-lateral surface 3 of the urothelium 1 is located a $\text{Na}^+ - \text{K}^+$ ATPase antiport system 9, that may be inhibited by the action of ouabain. The presence and correct spatial location of these ion transport systems can be determined through electro-physiological studies by measuring the amiloride-sensitive and ouabain-sensitive potential difference across isolated urothelium.

Thus, the following features are indicative of functional urothelium:

- (1) The stratified morphology of basal, intermediate, and "umbrella" cells,
- (2) The presence of uroplakin protein plaques on the apical surface of the membrane,
- (3) The presence of tight junctions between the cells of the membrane,
- (4) The spatially-correct location of amiloride-sensitive sodium channels, and basolateral expression of $\text{Na}^+ - \text{K}^+$ ATPase,
- (5) A high transepithelial resistance,
- (6) Low passive permeability to other small and large molecular weight species.

A recent review of the state of knowledge of bladder epithelium (urothelium) is provided by Lewis (American Journal of Physiology – Renal Physiology, 2000, 278: F867-F874).

There would be considerable advantage in being able to produce *in vitro* cultivated urothelium, for a number of reasons. It would provide a model for the study of both normal physiological, and pathophysiological function; it would provide a model for the study of action of pharmaceutical compounds, for example as part of the process of drug discovery (current methods include the use of either undifferentiated or tumour cell culture, neither of which is regarded as a good model for the natural tissue); it would also provide a model for toxicological testing, including but not limited to the assessment of oncogenic potential of substances; it would also provide material for use in reconstructive surgery.

Undifferentiated primary cultures of urothelial cells were first propagated *in vitro* in the early 1980's, and since then numerous attempts have been made to develop a functional mammalian urothelial cell culture model. However, despite a number of advances, no system has thus far been described in which the *in vitro*-generated

urothelium morphologically and functionally resembles native urothelium, as discussed above.

5 In 1993 a method was disclosed (K.R. Hutton *et al*, the Journal of Urology, Volume 150, 71-75, August 1993) for urothelial tissue culture. Urothelium was isolated from clinical tissue samples, by micro-dissection and the use of proteolytic enzymes. The detached urothelium sheets were further treated with collaganase to yield a single cell suspension. The cells could be successfully cultivated on serum-free medium for at least 7 passages. Although confluent
10 sheets of urothelial cells could be produced by this method, no evidence of stratification of the epithelium was observed, and indeed immuno-labelling with differentiation-associated antibody markers demonstrated that although the cultured cells expressed a basal/intermediate cell phenotype, there was no evidence of terminal differentiation.

15 In a study published in 1994, Southgate *et al* (Laboratory Investigation, Vol. 71, No 4, Page 583) disclosed the effect of increasing calcium concentration on the stratification of *in vitro* cultured human urothelial cells. In this study, the tissue samples from renal pelvis, urinary bladder, and ureter were obtained from a total
20 of 62 patients with an age range of 3 months to 23.2 years. Single cell cultures of urothelium were obtained by treatment of tissue with EDTA (ethylenediaminetetraacetic acid) followed by enzymatic digestion. Increasing the extra-cellular calcium concentration in the serum-free growth medium was found to have a marked effect on urothelial cell morphology in all the cell lines
25 examined. Increasing the calcium concentration from 0.09mM to 2.0mM induced the stratification of the cultured cells, although, despite the multi-layering and evidence of the formation of tight junctions, no AUM was seen in the superficially positioned cells, indicating that late or terminal differentiation had not been obtained. The study did demonstrate, however that donor age is not an
30 important factor for successful urothelial cell culture. Furthermore no discernible

differences were observed in the growth properties and phenotype of cultured urothelia initiated from tissue samples from different regions of the urinary tract.

5 In a study published in 1997, Liebert and her co-workers (Liebert *et al*,
Differentiation, 1997, 61: 177-185) cultured urothelial cells on a serum-free
growth medium, and then studied their characteristics after transfer to growth
medium supplemented with 2% foetal and 8% newborn calf serum. Although the
study appeared to demonstrate a high transepithelial electrical resistance (albeit by
the use of the not particularly reliable method of "chopstick" electrodes) no
10 cellular differentiation was reported using any recognised urothelium-specific
markers.

In order to compare the relative effectiveness of the method disclosed in Liebert *et al*,
with the present invention, the following study has been undertaken: primary
15 cultures of human urothelium cells were established in serum-free medium as
described below. A sample of the cells was plated onto membrane filters, and
transferred to cell culture medium containing bovine serum. This is in essence the
protocol of Liebert *et al*. A second sample of the cells was passaged into serum-
containing medium according to the preferred embodiment of the current
20 invention described below, before plating onto snapwell membranes, and
incubating, again in serum-containing medium as described below. Following
seven days growth of the cells the transepithelial electrical resistance of the tissue
produced was assessed by use of a modified Ussing chamber and an electric volt-
ohm meter. The TER of the tissue cultivated by essentially the protocol of Liebert
25 *et al* showed a TER of $18.6 \Omega \text{ cm}^2$. By contrast, replicate samples of urothelium
tissue produced by the method of the current invention showed a mean TER of
 $3023.4 \Omega \text{ cm}^2$. Thus, the former method failed to produce high transepithelial
resistance characteristic of functional urothelium.

In 2000 Sugasi and co-workers (The Journal of Urology, Vol. 164, 951-957, September 2000) described the *in vitro* engineering of human urothelium. Urothelial cells were obtained from tissue samples by separating the urothelium from the underlying stroma, separating the cells by use of collagenase, and culturing the cells in Keratinocyte Serum-Free Medium (KSFM), supplemented with recombinant epithelial growth factor, bovine pituitary extract, cholera toxin and antibiotics. Upon reaching 100% confluence the serum-free medium was enriched with calcium to a final concentration of 1.5mM to induce stratification. This procedure had already been demonstrated to induce stratification by Southgate *et al*, 1994, (cited above) but does not induce urothelial differentiation.

Summary of the Invention

In the broadest definition of the invention, there is provided the production of stratified, differentiated mammalian urothelium in which urothelium cells are passaged through a nutrient medium containing the components of serum and redispersed before going on in a like medium to form said urothelium. Preferably, the mammalian urothelium is human urothelium.

Preferably also, the serum is bovine serum, and more preferably the serum is foetal bovine serum.

Advantageously, the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 1% and about 30% related to the concentration of said components in whole serum. More advantageously, the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 3% and about 10% related to the concentration of said components in whole serum. Most advantageously, the concentration of the components of serum as a proportion of the final volume of

nutrient medium is between about 4% and about 6% related to the concentration of said components in whole serum.

5 Preferably also, the nutrient medium is, or is a derivative of, MCDB-153 medium. More preferably, the nutrient medium is KSFM (Keratinocyte Serum Free Medium).

Advantageously, the nutrient medium is supplemented by one or more of Epidermal Growth Factor (EGF); Bovine Pituitary Extract (BPE); Cholera Toxin (CT), for reasons described below.

10

Included within the scope of the invention is a process for the production of mammalian urothelium substantially as described herein.

15

Another aspect of the invention is urothelium produced by the invention, as described above.

Brief Description of the Drawings

20

Figure 1 shows a schematic diagram of a section through typical, functional urothelium, as previously mentioned.

Figure 2 is a graph showing the dose-responsive decrease in short circuit current across urothelium on the addition of amiloride to the apical surface.

25

Description of the Preferred Embodiment

The preferred embodiment of the invention will now be described by means of a description of each of the phases of the method.

Sources of Tissue

5 Urothelium lines the urinary tract from the renal pelvis through the ureter and bladder to the first part of the urethra. Urothelial cell cultures can be generated readily from each of these regions and no major differences have been found in cell cultures established from different regions of the urinary tract or from adult or paediatric donors. Preferably, tissue for urothelial cell culture can be obtained from biopsies taken under local anaesthetic or from tissue removed at surgery. Diathermy should be avoided in the area round the tissue to be harvested, as this adversely affects the cell viability. Alternatively, urothelial cells may be obtained from samples of urine, using appropriate methods of either cell identification, cell selection or cell sorting, to ensure the cells collected are indeed of urothelial origin. Also, urothelial tissues may be harvested from cadavers, as described by Schmidt and co-workers (Journal of Urology, 1984, 132:1262-1264).

15 The urothelium is separated from any attached stroma by any of a number of methods recognised by those skilled in the art. Preferably, the specimen of urothelium is trimmed to remove serosa, fat, or other debris, and transferred into a stripping solution comprising HEPES buffer, a protease inhibitor such as aprotinin, EDTA (ethylenediaminetetraacetic acid, disodium salt) and HBSS (Hank's balanced salt solution) without calcium and magnesium. A detailed description of this methodology is described in Southgate J., Masters, J.R.W., and Trejdosiewicz, L.K., "Culture of Human Urothelium", In: Freshney, R.I. and Freshney, M.G., (Eds.) "Culture of Epithelial Cells", 2nd edition, 2002, John Wiley & Sons Inc.

25 Alternatively, the urothelial cells can be separated from the underlying stroma by mechanical scraping of the urothelial surface of the tissue samples.

Primary Urothelial Cell Culture

5 If the urothelial cell material has been isolated as urothelial sheets as described in the preceding section, or is in the form of aggregated cells isolated from urine, a culture of dispersed cells may be obtained by any of the methods well known in the art. Collagenase may be used, if required, to release the cells from the underlying tissues.

10 Suitable medium for the culture and sub-culture of the urothelial cells include KSFM (keratinocyte serum-free medium); MEM (minimal essential medium); and other similar low calcium media suitable for culture of keratinocytes, and preferably based on MCDB-153 medium, and optionally, but preferably containing supplements as described in Southgate *et al* (Laboratory Investigation, 71(4), 583-594, 1994), drawn from the following list:

15 (i) Epidermal Growth Factor (EGF), preferably human recombinant EGF, at a final concentration of about 0.05 to about 0.5 ng/ml. Urothelial cells express genes for EGF receptors, and EGF has been demonstrated to be a growth factor for urothelial cells, and gives longevity to the cell lines.

20 (ii) Bovine Pituitary Extract (BPE), at a concentration of about 10 to about 50 µg/ml, which is required for the long-term survival of urothelial cell lines.

(iii) Cholera Toxin (CT), at a concentration of about 10 to about 75, and preferably about 30 ng/ml, which improves the plating efficiency of the primary culture.

25 Suitable antibiotics to control the growth of contaminating organisms may also be added, although such additions may mask the presence of such contaminating organisms without eliminating them, and so their absence is to be preferred.

The urothelial cells may then be grown in a substantially conventional way, and maintained by serial sub-culture, or passage, most preferably before the cells reach 100% confluence. The primary, and substantially undifferentiated, cell culture thus attained may be maintained for extended periods of time by such sequential sub-culture, or passage.

Induction of Stratification and Terminal Differentiation

In order to induce stratification and differentiation of the cell culture, cells from the primary cell culture described above are, according to the method of this invention, passaged through a differentiation medium. The differentiation medium of this invention will comprise in addition to a standard cell culture medium (such as KSFM, MEM and other similar low calcium media suitable for culture of keratinocytes, and preferably based on MCDB-153 medium) the components of serum, preferably bovine serum, and more preferably foetal bovine serum, in a concentration from about 1% to about 30%, preferably about 5%, by volume, said percentages being based on the total volume of the differentiation medium, and related to the concentration of said serum components in whole serum. Although said serum is most preferably incorporated as a component of said differentiation medium prior to introducing the urothelial cells into the differentiation medium, it may optionally be added to the medium at any time up to about 5 hours after introduction of the urothelial cells into the medium.

In addition, said differentiation medium may optionally, but preferably contain supplements as described in Southgate *et al* (Laboratory Investigation, 71(4), 583-594, 1994), drawn from the following list:

(i) Epidermal Growth Factor (EGF), preferably human recombinant EGF, at a final concentration of about 0.05 to about 0.5 ng/ml. Urothelial cells express

genes for EGF receptors, and EGF has been demonstrated to be a growth factor for urothelial cells, and gives longevity to the cell lines.

(ii) Bovine Pituitary Extract (BPE), at a concentration of about 10 to about 50 $\mu\text{g/ml}$, which is required for the long-term survival of urothelial cell lines.

5 (iii) Cholera Toxin (CT), at a concentration of about 10 to about 75, and preferably about 30 ng/ml , which improves the plating efficiency of the primary culture.

10 Suitable antibiotics to control the growth of contaminating organisms may also be added, although such additions may mask the presence of such contaminating organisms without eliminating them, and so their absence is to be preferred.

15 In order to induce stratification and differentiation by the method of this invention, cells from the primary cell culture described above are disaggregated by means well known in the art, for example by use of trypsin and EDTA. For an example of a suitable protocol for disaggregation, see Southgate *et al* ("Culture of Human Urothelium", as above). The disaggregated cells are transferred to the said differentiation medium, and incubated in a substantially conventional manner until they approach confluency. Following this passage through said serum-
20 containing differentiation medium, the cells are once more disaggregated in a substantially conventional manner, and again transferred to fresh serum-containing differentiation medium. This medium, seeded with the urothelial cells, may then be incubated in any substantially conventional cell culture apparatus, or alternatively plated onto any suitable support device, such as polycarbonate
25 Snapwell filters. Following incubation for between about 1 hour and about 48 hours, preferably about 24 hours, the calcium concentration in the growth medium is increased to between about 0.2mM, and about 5mM, preferably about 2mM. Over the following few days, typically after 7 days, the cells will grow to form a substantially functional and terminally-differentiated urothelium. At this stage, the

urothelium may be characterised according to morphological and functional criteria as described below.

5 Example: Production and Characterisation of Human Urothelium according to the Method of the Invention

10 **Production of Human Urothelium.** *In vitro*, primary, undifferentiated cultures of human urothelial cells were established and propagated through serial passage in serum-free, low calcium KSFM (Gibco BRL, Paisley, UK) culture medium, as described by Southgate *et al* ("Culture of Epithelial Cells", cited above) using donor tissue from a number of human sources. After sufficient cells were generated (after two to four passages), the cells were harvested and seeded into KSFM medium supplemented with 5% by volume foetal bovine serum (FBS). At confluency, the urothelial cells were harvested, and seeded onto Snapwell filters, and maintained in KSFM medium, supplemented with 5% FBS. After 24 hours, the calcium concentration of the medium was increased from 0.09mM to 2mM. The phenotype and various functional properties of the urothelial cell cultures were assessed at seven days subsequent to seeding onto the filters. The results of these characterisations are described below.

20 **Phenotypic Characterisation.** Microscopic examination of the cultivated urothelium revealed the stratified, and terminally differentiated nature of the urothelium produced by the method of this invention. Particular features clearly evident to a person skilled in the art of mammalian histology included the presence of stratified layers of basal, intermediate and umbrella cells, and the presence of tight junctions between the urothelial cells. The use of indirect immunofluorescence analysis further confirmed the formation of intercellular tight junctions indicated by the presence of the tight junction protein occludin.

30 **Transepithelial Electrical Resistance (TER).** The transurothelial electrical resistance of the *in vitro* urothelium produced by the method of the invention was

measured using a modified Ussing chamber and an electronic volt-ohm meter. The TER of *in vitro* cultivated urothelium produced by the method of this invention was measured on samples produced on seven separate occasions. The mean TER was found to be $3023.4 \pm 564.4 \Omega \text{ cm}^2$. By contrast, confluent layers of urothelial cells cultured on KSFM medium alone were found to have a TER of $12.7 \pm 1.9 \Omega \text{ cm}^2$.

Transurothelial Permeability. The diffusive water and urea permeabilities of the urothelial sheet produced by the method of this invention were determined using a radio isotope tracer technique. The mean permeability to urea and water respectively were 10.1×10^{-5} centimetres per second and 4.5×10^{-4} centimetres per second. These measured permeabilities were statistically significantly smaller than those obtained for urothelial sheet cultured on KSFM medium alone, these being 12.7×10^{-5} centimetres per second and 5.2×10^{-4} centimetres per second for urea and water respectively.

Polarised Sodium Ion Channel Distribution. In order to determine the presence and correct spatial location of sodium ion channels, short circuit current and transepithelial potential difference were measured under voltage and current clamped conditions respectively. The exposure of the apical surface of the urothelial tissue to amiloride reduced both the voltage and the current in a dose-dependent manner. Figure 2 shows the dose-dependent decrease in short circuit current as a function of the amiloride concentration at the apical surface. Exposure of the basal surface of the urothelial membrane to amiloride did not affect either the voltage or the current. These results indicate that the amiloride-sensitive sodium channels were located on, and restricted to the apical membrane, as required in functional urothelium. Exposure of the apical surface of the *in vitro* cultivated urothelium to ouabain had only a minor effect on the measured voltage and current. By contrast, when the basal surface of the membrane was exposed to

ouabain, there was a marked reduction of both voltage and current, indicating the correct baso-lateral positioning of the $\text{Na}^+\text{-K}^+$ ATPase.

5 ***Expression of AUM Protein.*** The expression of the uroplakin UPIa, UPIb, and UPII genes in the *in vitro* cultivated urothelium of the present invention was confirmed at the mRNA level by the use of reverse transcriptase PCR with appropriate primers.

10 The above characterisation of the phenotypic and functional characteristics of urothelial tissue produced by the method of the current invention demonstrates the urothelium so produced exhibits more of the functional characteristics of native urothelium than is demonstrated in any of the methods known in the prior art. The observation that researchers skilled in the art of both mammalian cell culture and, more specifically, urothelial cell culture, have attempted to produce functional *in*
15 *vitro* urothelium for almost 20 years without success, is testament to the inventiveness of the invention described here.

The invention so described is envisaged to be applicable to the production of mammalian, including human, urothelium.

20 Various publications are cited herein, the disclosure of which are incorporated by reference in their entireties.

Claims

1. Production of stratified, differentiated mammalian urothelium in which urothelium cells are passaged through a nutrient medium containing the components of serum and redispersed before going on in a like medium to form said urothelium.
2. The invention of Claim 1 wherein the mammalian urothelium is human urothelium.
3. The invention of either Claim 1 or Claim 2 in which the serum is bovine serum.
4. The invention of either Claim 1 or Claim 2 in which the serum is foetal bovine serum.
5. The invention of any of the preceding Claims in which the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 1% and about 30% related to the concentration of said components in whole serum.
6. The invention of any of Claim 1 to Claim 4 in which the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 3% and about 10% related to the concentration of said components in whole serum.
7. The invention of any of Claim 1 to Claim 4 wherein the concentration of the components of serum as a proportion of the final volume of nutrient medium is between about 4% and about 6% related to the concentration of said components in whole serum.
8. The invention of any of the preceding Claims wherein the nutrient medium is, or is a derivative of, MCDB-153 medium.
9. The invention of any of Claim 1 to Claim 7 wherein the nutrient medium is KSFM (Keratinocyte Serum Free Medium).
10. The invention of any of the preceding Claims wherein the nutrient medium is supplemented by one or more of Epidermal Growth Factor (EGF); Bovine Pituitary Extract (BPE); Cholera Toxin (CT).

11. A process for the production of mammalian urothelium substantially as described herein.

12. Urothelium produced by the invention of any of the above Claims.

Abstract**BIOMIMETIC UROTHELIUM**

5 Urothelium is the specialised endothelium that lines much of the mammalian
urinary tract. This invention relates to the field of *in vitro* urothelial culture.
Previous methods produce tissue lacking much of the functionality of native
urothelium. In this invention, stratified, differentiated mammalian urothelium 1 is
10 produced by passaging urothelial cells through a nutrient medium containing serum,
and redispersed, before going on in a like medium to form said urothelium.

Figure 1 should accompany the abstract.




Figure 2

